TABLE 1.
Demographic characteristics of women in the IMPROVE study at study entry
| Characteristic | VM group (n = 152) | BM group (n = 148) |
|---|---|---|
| Age (years), mean ± SD | 28.2 ± 6.4 | 27.6 ± 6.4 |
| Site, n (%) | ||
| Eskenazi | 86 (56.6) | 83 (56.1) |
| Methodist | 66 (43.4) | 65 (43.9) |
| Nulliparous women, n (%) | 59 (38.8) | 65 (43.9) |
| Race/ethnicity, n (%) | ||
| White | 74 (48.7) | 66 (44.6) |
| African American | 45 (29.6) | 49 (33.1) |
| Other | 33 (21.7) | 33 (22.3) |
| Ethnicity, n (%) | ||
| Hispanic/Latino | 42 (27.6) | 44 (29.7) |
| Non-Hispanic/non-Latino | 109 (71.7) | 99 (66.9) |
| Prefer not to answer | 1 (0.7) | 5 (3.4) |
| BMI (kg/m2), mean ± SD | 35.7 ± 7.2 | 35.1 ± 7.3 |
| BMI category, n (%) | ||
| <18 | 0 | 1 (0.7) |
| 18–25 | 7 (4.6) | 12 (8.1) |
| 25–30 | 22 (14.5) | 22 (14.9) |
| 30–40 | 87 (57.2) | 77 (52.0) |
| >40 | 36 (23.7) | 36 (24.3) |
| Gestational age at trial entry (weeks), mean ± SD | 39.6 ± 1.3 | 39.5 ± 1.3 |
| Indication for induction, n (%) | ||
| Fetal indications | 10 (6.6) | 17 (11.5) |
| Hypertensive disorder | 33 (21.7) | 31 (21.0) |
| Diabetes mellitus | 10 (6.6) | 20 (13.5) |
| Late-term pregnancy (≥41+0 weeks) | 44 (29.0) | 36 (24.3) |
| Elective | 21 (13.8) | 13 (8.8) |
| Multiple reasons | 13 (8.6) | 13 (8.8) |
| Other | 21 (13.8) | 18 (12.2) |
| Epidural, n (%) | 127 (83.6) | 122 (82.4) |
| Cervical dilation, n (%) | ||
| <1 cm | 31 (20.7) | 37 (25.2) |
| 1–2 cm | 102 (68) | 89 (60.6) |
| >2 cm | 17 (11.3) | 21 (14.3) |
| Cervical dilation (cm), mean ± SD | 1.3 ± 0.9 | 1.3 ± 0.9 |
| Effacement of cervix, n (%) | ||
| 0–30% or >4 cm length | 82 (54.7) | 82 (55.8) |
| 40–50% or 3–4 cm length | 62 (41.3) | 52 (35.4) |
| 60–70% or 1–2 cm length | 5 (3.3) | 10 (6.8) |
| Effacement of cervix measure (%), mean ± SD | 31.7 ± 20.8 | 31.8 ± 22.8 |
| Fetal station (cm), n (%) | ||
| −3 | 106 (72.1) | 106 (72.6) |
| −2 | 34 (23.1) | 36 (24.7) |
| −1,0 | 7 (4.8) | 4 (2.7) |
| Fetal station (cm), mean ± SD | −2.8 ± 0.8 | −2.8 ± 0.7 |
| Bishop score, mean ± SD | 2.3 ± 1.7 | 2.2 ± 1.7 |
No statistically significant differences in any baseline characteristics between groups.
BM, buccal misoprostol; BMI, body mass index; VM, vaginal misoprostol.